Asia-Pacific Natural Killer (NK) Cell Therapeutics Market – Industry Trends and Forecast to 2027

  • Pharmaceutical
  • Published Report
  • Nov 2020
  • Asia-Pacific
  • 350 Pages
  • No of Tables: 107
  • No of Figures: 40

Asia-Pacific Natural Killer (NK) Cell Therapeutics Market, By Therapeutics (NK Cell Therapies, NK Cell Directed Antibodies), Approaches (Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC), Bispecific Antibodies), Application (Cancer, Acute Infectious Diseases, Immunoproliferative Disorders, Gastrointestinal Diseases, Others), End User (Hospitals, Specialty Clinics, Research & Academic Institutes), Distribution Channel (Hospital Pharmacies, Direct Tender, Others), Country (Hospital Pharmacies, Direct Tender, Others), Country (Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific) Industry Trends & Forecast to 2027

Asia-Pacific Natural Killer (NK) Cell Therapeutics Market Market Analysis and Insights : Asia-Pacific Natural Killer (NK) Cell Therapeutics Market

Asia-Pacific natural killer (NK) cell therapeutics is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses that the market is growing with a CAGR of 42.6% in the forecast period of 2020 to 2027 and is expected to reach USD 170.05 million by 2027. Increase In usage of natural killer (NK) cell for the treatment of cancer and infectious diseases and presence of pipeline products are the major drivers which propelled the demand of the market in the forecast period.

Natural killer (NK) cell therapeutics comprises features such as increasing need for better therapeutic options which will impact in launching new products by the manufacturers into the market which enhance its demand as well as increasing investment in research and development leads to the natural killer (NK) cell therapeutics market growth.

Currently, various research studies are taking place which is expected to create a competitive advantage for manufacturers to develop new and innovative natural killer (NK) cell therapeutics which is expected to provide various other opportunities in the natural killer (NK) cell therapeutics market. However, long approval time for immunotherapies and adverse side effects of therapies are expected to restraint the natural killer (NK) cell therapeutics market growth in the forecast period.

The natural killer (NK) cell therapeutics market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the natural killer (NK) cell therapeutics market scenario contact Data Bridge Market Research for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Asia-Pacific Natural Killer (NK) Cell Therapeutics Market Asia-Pacific Natural Killer (NK) Cell Therapeutics Market Scope and Market Size

Natural killer (NK) cell therapeutics market is segmented on the basis of therapeutics, approaches, application, end-user and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

  • On the basis of therapeutics, the natural killer (NK) cell therapeutics market is segmented into NK cell therapies and NK cell directed antibodies. In 2020, NK cell therapies segment is dominating the market because these are widely used therapies for treatment of malignancies as well as proved safe and effective treatment options.
  • On the basis of approaches, the natural killer (NK) cell therapeutics market is segmented into antibody-dependent cell-mediated cytotoxicity (ADCC) and bispecific antibodies. In 2020, antibody-dependent cell-mediated cytotoxicity (ADCC) segment is dominating the market as it is an off-the-shelf approach used in order to enhance the NK cells toxicity level.
  • On the basis of application, the natural killer (NK) cell therapeutics market is segmented into cancer, acute infectious diseases, immunoproliferative disorders, gastrointestinal diseases and others. In 2020, cancer segment is dominating the market as NK cells therapies have the potential to kill nearby cancer cells by secreting cytokines and by recruiting T-cells and dendritic cells.
  • On the basis of end user, the natural killer (NK) cell therapeutics market is segmented into hospitals, specialty clinics and research & academic institutes. In 2020, hospitals segment is dominating the market as various clinical trials are conducted at hospitals in order to prove the safety and efficacy of NK cell therapies.
  • On the basis of distribution channel, the natural killer (NK) cell therapeutics market is segmented into hospital pharmacies, direct tender and others. In 2020, hospital pharmacies segment is dominating the market as these pharmacies supply all type of medicines as per the patient’s needs.

Asia-Pacific Natural Killer (NK) Cell Therapeutics Market Country Level Analysis

Natural killer (NK) cell therapeutics market is analyzed and market size information is provided by the country, therapeutics, approaches, application, end-user and distribution channel as referenced above.

The countries covered in the Asia-Pacific natural killer (NK) cell therapeutics market report are the Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific.

  • In Asia-Pacific region hospital pharmacies is expected to grow in China with the highest growth rate in the forecast period of 2020 to 2027 because the NK cell therapeutics are the prescription based drugs and can be purchased from the pharmacies. Japan is leading the growth of the Asia-Pacific market and medication segment is dominating in this country due to rise in prevalence of cancer such as lymphomas.

The country section of the Asia-Pacific natural killer (NK) cell therapeutics market report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of Asia-Pacific brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Strategic Initiative by Market Players and Adoption of Natural Killer (NK) Cell Therapy in Emerging Markets are Boosting the Market Growth of Natural Killer (NK) Cell Therapeutics Market

Asia-Pacific natural killer (NK) cell therapeutics market also provides you with detailed market analysis for every country growth in natural killer (NK) cell therapeutics industry with natural killer (NK) cell therapeutics drugs sales, impact of advancement in the natural killer (NK) cell therapeutics technology and changes in regulatory scenarios with their support for the natural killer (NK) cell therapeutics market. The data is available for historic period 2010 to 2018.

Competitive Landscape and Asia-Pacific Natural Killer (NK) Cell Therapeutics Market Share Analysis

Natural Killer (NK) cell therapeutics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to natural killer (NK) cell therapeutics market.

The major companies which are dealing in the Asia-Pacific natural killer (NK) cell therapeutics market are Phio Pharmaceuticals Gamida Cell, Acepodia Inc., Bristol-Myers Squibb Company, iCell Gene Therapeutics, Takeda Pharmaceutical Company Limited, NantKwest and Merck KGaA among others. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Many product launch and agreement are also initiated by the companies’ worldwide which are also accelerating the natural killer (NK) cell therapeutics market.

For instance,

  • In May 2020, Phio Pharmaceuticals obtained positive data from invivo study of PH-804 against the tumor microenvironment. This platform has the potential to activate NK cells and enhances its cytotoxic activity, which leads to treatment of solid tumors.

Collaboration, product launch, business expansion, award and recognition, joint ventures and other strategies by the market player is enhancing the company market in the natural killer (NK) cell therapeutics market which also provides the benefit for organization to improve their offering for natural killer (NK) cell therapeutics.

Customization Available: Asia-Pacific Natural Killer (NK) Cell Therapeutics Market

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.


SKU-

LIST OF TABLES

TABLE 1 ASIA-PACIFIC NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, PIPELINE ANALYSIS

TABLE 2 ASIA-PACIFIC NATURAL KILLER (NK) CELL THERAPEUTICS MARKET: EXPECTED PRODUCT LAUNCH DATE

TABLE 3 TOTAL HEALTH SPENDING BY THE U.S. (2015-2016)

TABLE 4 ASIA-PACIFIC NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY THERAPEUTICS, 2019-2027 (USD MILLION)

TABLE 5 ASIA-PACIFIC NK CELL THERPAIES IN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 6 ASIA-PACIFIC NK CELL DIRECTED ANTIBODIES IN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 7 ASIA-PACIFIC NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPROACHES, 2019-2027 (USD MILLION)

TABLE 8 ASIA-PACIFIC ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY (ADCC) IN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 9 ASIA-PACIFIC BI-SPECIFIC ANTIBODIES IN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 10 ASIA-PACIFIC NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2019-2027 (USD MILLION)

TABLE 11 ASIA-PACIFIC CANCER IN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 12 ASIA-PACIFIC CANCER IN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 13 ASIA-PACIFIC HEMATOLOGIC MALIGNANCIES IN CANCER NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 14 ASIA-PACIFIC NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY END USER, 2019-2027 (USD MILLION)

TABLE 15 ASIA-PACIFIC HOSPITALS IN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 16 ASIA-PACIFIC SPECIALTY CLINICS IN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 17 ASIA-PACIFIC RESEARCH AND ACADEMIC INSTITUTES IN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 18 ASIA-PACIFIC NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 19 ASIA-PACIFIC HOSPITAL PHARMACIES IN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 20 ASIA-PACIFIC DIRECT TENDER IN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 21 ASIA-PACIFIC OTHERS IN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 22 ASIA-PACIFIC NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY COUNTRY, 2018-2027 (USD MILLION)

TABLE 23 ASIA-PACIFIC NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY THERAPEUTICS, 2018-2027 (USD MILLION)

TABLE 24 ASIA-PACIFIC NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPROACHES, 2018-2027 (USD MILLION)

TABLE 25 ASIA-PACIFIC NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 26 ASIA-PACIFIC CANCER NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 27 ASIA-PACIFIC HEAMTOLOGICAL MALIGNANCIES IN CANCER NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 28 ASIA-PACIFIC NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY END USER 2018-2027 (USD MILLION)

TABLE 29 ASIA-PACIFIC NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 30 JAPAN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY THERAPEUTICS, 2018-2027 (USD MILLION)

TABLE 31 JAPAN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPROACHES, 2018-2027 (USD MILLION)

TABLE 32 JAPAN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 33 JAPAN CANCER NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 34 JAPAN HEAMTOLOGICAL MALIGNANCIES IN CANCER NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 35 JAPAN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY END USER 2018-2027 (USD MILLION)

TABLE 36 JAPAN NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 37 CHINA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY THERAPEUTICS, 2018-2027 (USD MILLION)

TABLE 38 CHINA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPROACHES, 2018-2027 (USD MILLION)

TABLE 39 CHINA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 40 CHINA CANCER NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 41 CHINA HEAMTOLOGICAL MALIGNANCIES IN CANCER NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 42 CHINA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY END USER 2018-2027 (USD MILLION)

TABLE 43 CHINA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 44 AUSTRALIA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY THERAPEUTICS, 2018-2027 (USD MILLION)

TABLE 45 AUSTRALIA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPROACHES, 2018-2027 (USD MILLION)

TABLE 46 AUSTRALIA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 47 AUSTRALIA CANCER NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 48 AUSTRALIA HEAMTOLOGICAL MALIGNANCIES IN CANCER NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 49 AUSTRALIA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY END USER 2018-2027 (USD MILLION)

TABLE 50 AUSTRALIA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 51 SOUTH KOREA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY THERAPEUTICS, 2018-2027 (USD MILLION)

TABLE 52 SOUTH KOREA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPROACHES, 2018-2027 (USD MILLION)

TABLE 53 SOUTH KOREA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 54 SOUTH KOREA CANCER NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 55 SOUTH KOREA HEAMTOLOGICAL MALIGNANCIES IN CANCER NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 56 SOUTH KOREA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY END USER 2018-2027 (USD MILLION)

TABLE 57 SOUTH KOREA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 58 INDIA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY THERAPEUTICS, 2018-2027 (USD MILLION)

TABLE 59 INDIA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPROACHES, 2018-2027 (USD MILLION)

TABLE 60 INDIA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 61 INDIA CANCER NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 62 INDIA HEAMTOLOGICAL MALIGNANCIES IN CANCER NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 63 INDIA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY END USER 2018-2027 (USD MILLION)

TABLE 64 INDIA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 65 SINGAPORE NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY THERAPEUTICS, 2018-2027 (USD MILLION)

TABLE 66 SINGAPORE NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPROACHES, 2018-2027 (USD MILLION)

TABLE 67 SINGAPORE NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 68 SINGAPORE CANCER NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 69 SINGAPORE HEAMTOLOGICAL MALIGNANCIES IN CANCER NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 70 SINGAPORE NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY END USER 2018-2027 (USD MILLION)

TABLE 71 SINGAPORE NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 72 MALAYSIA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY THERAPEUTICS, 2018-2027 (USD MILLION)

TABLE 73 MALAYSIA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPROACHES, 2018-2027 (USD MILLION)

TABLE 74 MALAYSIA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 75 MALAYSIA CANCER NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 76 MALAYSIA HEAMTOLOGICAL MALIGNANCIES IN CANCER NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 77 MALAYSIA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY END USER 2018-2027 (USD MILLION)

TABLE 78 MALAYSIA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 79 THAILAND NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY THERAPEUTICS, 2018-2027 (USD MILLION)

TABLE 80 THAILAND NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPROACHES, 2018-2027 (USD MILLION)

TABLE 81 THAILAND NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 82 THAILAND CANCER NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 83 THAILAND HEAMTOLOGICAL MALIGNANCIES IN CANCER NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 84 THAILAND NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY END USER 2018-2027 (USD MILLION)

TABLE 85 THAILAND NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 86 INDONESIA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY THERAPEUTICS, 2018-2027 (USD MILLION)

TABLE 87 INDONESIA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPROACHES, 2018-2027 (USD MILLION)

TABLE 88 INDONESIA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 89 INDONESIA CANCER NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 90 INDONESIA HEAMTOLOGICAL MALIGNANCIES IN CANCER NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 91 INDONESIA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY END USER 2018-2027 (USD MILLION)

TABLE 92 INDONESIA NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 93 PHILIPPINES NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY THERAPEUTICS, 2018-2027 (USD MILLION)

TABLE 94 PHILIPPINES NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPROACHES, 2018-2027 (USD MILLION)

TABLE 95 PHILIPPINES NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 96 PHILIPPINES CANCER NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 97 PHILIPPINES HEAMTOLOGICAL MALIGNANCIES IN CANCER NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 98 PHILIPPINES NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY END USER 2018-2027 (USD MILLION)

TABLE 99 PHILIPPINES NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 100 VIETNAM NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY THERAPEUTICS, 2018-2027 (USD MILLION)

TABLE 101 VIETNAM NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPROACHES, 2018-2027 (USD MILLION)

TABLE 102 VIETNAM NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 103 VIETNAM CANCER NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 104 VIETNAM HEMATOLOGIC MALIGNANCIES IN CANCER NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 105 VIETNAM NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY END USER 2018-2027 (USD MILLION)

TABLE 106 VIETNAM NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 107 REST OF ASIA- PACIFIC NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY THERAPEUTICS, 2018-2027 (USD MILLION)

 

CHOOSE LICENCE TYPE
  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 7500.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions